News

Video

Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study

CROWN (NCT03052608) is a phase 3 clinical trial evaluating progression free survival with the use of loratinib in patients with advanced ALK+ NSCLC.

Related Videos
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
4 KOLs are featured in this series
4 KOLs are featured in this series
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM)
5 KOLs are featured in this peer exchange
5 KOLs are featured in this peer exchange
utinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis